Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

International, national and local partners have been welcomed to the launch of the world’s first centre dedicated to empowering global epilepsy research and care.

Professor Arjune Sen speaking at lectern. © Wolfson College / Centre for Global Epilepsy

Researchers from academic institutions in Africa, South America, the United States, and Europe congregated to celebrate the launch and demonstrate their commitment to global epilepsy research and care.

Based at Wolfson College within the University of Oxford, and generously supported by the BAND Foundation, the Centre for Global Epilepsy will address the global burden of epilepsy, particularly in resource-limited settings. The centre collaborates with key research institutions and epilepsy clinics worldwide, linking expertise from high-income settings with those in resource-limited environments to drive advancements in epilepsy research, diagnosis, treatment, and care. In alignment with the World Health Organization’s Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders, the centre aims to foster global learning on epilepsy, provide immersive research opportunities in Oxford, and serve as a multidisciplinary hub for knowledge exchange.

Read the full story on the Oxford Martin School website.

Similar stories

60% of hepatitis C patients do not know how they had the disease

A survey at Vietnam's National Hospital for Tropical Diseases found 60% of hepatitis C patients unaware of how they contracted the disease, often diagnosed late. Globally, viral hepatitis causes 3,500 daily deaths, ranking second among infectious killers after tuberculosis.